REBEKAH HEYEN: Open Payments
NPI 1912603697 · CLINTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,894 in 97 payments from 17 companies in 2025. Trend: 2023 $1,083 · 2024 $1,947 · 2025 $1,894
Food & beverage: $1,894
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $312 |
| ABBVIE INC. | 15 | $263 |
| Alkermes, Inc. | 9 | $226 |
| Lilly USA, LLC | 8 | $154 |
| Amgen Inc. | 8 | $144 |
| Novo Nordisk Inc | 9 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| Braeburn Inc. | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, OTEZLA, JARDIANCE, TRINTELLIX, MAVYRET, BRIXADI.
Industry payments across IN — which companies pay providers there.
